The efficacy of ramelteon, selective melatonin receptor agonist, during the critical care: MELIt Trial (Melatonin Evaluation of Lowered Inflammation in ICU Trial)

The efficacy of ramelteon, selective melatonin receptor agonist, during the critical care: MELIt Trial (Melatonin Evaluation of Lowered Inflammation in ICU Trial) - MELIt Trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016541

Enrollment

180

Registered

2015-03-01

Start date

2015-03-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients who are at least 20 years, and are admitted to an emergency and medical ICU in our hospital.

Interventions

We give ramelteon to our emergency and medical ICU patients. We give placebo to our emergency and medical ICU patients.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients who are at least 20 years, and are admitted to an emergency and medical ICU in our hospital.

Exclusion criteria

Exclusion criteria: Exclusion criteria is the patient who is contraindicated for ramelteon, who is not receiving ramelteon therapy, who is admitted to our ICU during at least 2 days.

Design outcomes

Primary

Measure	Time frame
The primary outcome is the duration in our emergency and medical ICU admission.	—

Secondary

Measure	Time frame
Key secondary outcomes are 1. the transition of inflammation markers, 2. the incidence, severity of delirium, 3. the mortality rate when they are discharged from our emergency and medical ICU.	—

Countries

Japan

Contacts

Public ContactMitsuaki Nishikimi

Nagoya university hospital. The emergency and critical care department.

m0528332626@yahoo.co.jp+81-52-744-2659

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026